The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
JITC's editorial board is lead by Editor-in-Chief Dr. Pedro Romero of the University of Lausanne. From there, the journal is published with support from a throng of section and associate editors, who review their specific section areas. Click on a section name below to access the full editor list:
Editor-in-Chief
Pedro J. Romero, MD
University of Lausanne – Switzerland
Basic Tumor Immunology Section
Section Editor
Cornelis J.M. Melief, MD, PhD
ISA Therapeutics BV – Netherlands
Deputy Editor
Sjoerd H. van der Burg, PhD
Leiden University Medical Center – Netherlands
Associate Editors
Scott I. Abrams, PhD
Roswell Park Cancer Institute – United States
Paul A. Antony, MD
University of Maryland School of Medicine – United States
Timothy NJ Bullock, PhD
University of Virginia – United States
Gennaro Ciliberto, MD
IRCCS Istituto Nazionale Tumori 'Pascale' – Italy
Madhav Dhodapkar, MD
Yale University – United States
Norman M. Greenberg, PhD
Atreca – United States
Arthur A. Hurwitz, PhD
Agenus – United States
Masahisa Jinushi, MD, PhD
Merck & Co. – Japan
Khashayarsha Khazaie, PhD, DSc
Mayo Clinic College of Medicine – United States
Michelle Krogsgaard, PhD
NYU School of Medicine – United States
Maria Rescigno, PhD
European Institute of Oncology – Italy
Lillian Seu, PhD
Johns Hopkins University – United States
Andrew D. Weinberg, PhD
Earle A. Chiles Research Institute – United States
Case Reports Section
Section Editor
Alfred Zippelius, MD
University Hospital Basel – Switzerland
Associate Editors
Jack D. Bui, MD, PhD
University of California San Diego – United States
Richard D. Carvajal, MD
Columbia University Medical Center – United States
Matthew D. Hellmann, MD
Memorial Sloan Kettering Cancer Center – United States
Sebastian Kobold, MD
Ludwig Maximilian University of Munich – Germany
Heinz Laubli, MD, PhD
University Hospital Basel – Switzerland
Steven H. Lin, MD, PhD
University of Texas MD Anderson Cancer Center – United States
Andreas Mackensen, MD
University Hospital Erlangen – Germany
Olivier Michielin, MD, PhD
University of Lausanne – Switzerland
Hiroyoshi Nishikawa, MD, PhD
National Cancer Center – Japan
Michael von Bergwelt-Baildon, MD, PhD
University of Cologne – Germany
Geoffrey R. Weiss, MD
University of Virginia – United States
Hassane M. Zarour, MD
University of Pittsburgh – United States
Clinical/Translational Cancer Immunotherapy Section
Section Editors
James L. Gulley, MD, PhD, FACP
National Cancer Institute, National Institutes of Health – United States
Douglas G. McNeel, MD, PhD
University of Wisconsin Carbone Cancer Center – United States
Deputy Editor
Claudia Palena, PhD
National Cancer Institute, National Institutes of Health – United States
Associate Editors
Paulo Antonio Ascierto, MD
Istituto Nazional Tumori-Fondazione 'G.Pascale' – Italy
Ernest C. Borden, MD
Cleveland Clinic Foundation – United States
Jonathan L. Curry, MD
MD Anderson Cancer Center – United States
Lawrence Fong, MD
University of California, San Francisco – United States
Nancy M. Hardy, MD
National Cancer Institute, National Institutes of Health – United States
Christian S. Hinrichs, MD
National Cancer Institute, National Institutes of Health – United States
Pawel Kalinski, MD, PhD
Roswell Park Cancer Institute – United States
Yutaka Kawakami, MD
Keio University School of Medicine – Japan
Beatrix Kotlan, PhD
National Institute of Oncology – Hungary
Dung Le, MD
Johns Hopkins University – United States
Alessandro Lugli, MD
University of Bern – Switzerland
Ravi A. Madan, MD
National Cancer Institute, National Institutes of Health - United States
Michele Maio, MD, PhD
University Hospital of Siena – Italy
Giorgio Parmiani, MD
Fondaziones C.S. Raffaele Del Monte Tabor – Italy
Anna C. Pavlick, DO, MBA
NYU Cancer Institute – United States
Padmanee Sharma, MD, PhD
MD Anderson Cancer Center – United States
Jeffrey S. Weber, MD, PhD
NYU Longone Medical Center – United States
Yi-Long Wu, MD
Chinese Society of Clinical Oncology
Cassian Yee, MD
Fred Hutchinson Cancer Research Center – United States
Clinical Trials Monitor
Section Editor
Leisha A. Emens, MD, PhD
Johns Hopkins University – United States
Associate Editors
Stephen M. Ansell, MD, PhD
Mayo Clinic – United States
Jonathan S. Cebon, PhD
Ludwig Institute for Cancer Research – Australia
Tai-Tsang Chen, PhD
Columbia University; Bristol-Myers Squibb – United States
Jolanda de Vries, PhD
Radboud University Nijmegen – Netherlands
Silvia Formenti, MD
Weill Cornell Medical College – United States
Howard L. Kaufman, MD, FACS
Replimune Group Inc. – United States
Larry W. Kwak, MD, PhD
City of Hope – United States
Sherene Loi, MD, PhD
Peter MacCallum Cancer Centre – Australia
Kunle Odunsi, MD, PhD
Roswell Park Cancer Institute – United States
Michael A. Postow, MD
Memorial Sloan-Kettering Cancer Center – United States
Peter Schmid, MD, PhD
Imperial College London – United Kingdom
Hiroshi Shiku, MD
Mie University Graduate School of Medicine – Japan
Daniel E. Speiser, MD
Ludwig Institute for Cancer Research – Switzerland
Louis M. Weiner, MD
Georgetown University Lombardi Cancer Center – United States
Xiaobu Ye, MD, MS
Johns Hopkins University School of Medicine – United States
Commentary/Editorials Section
Section Editor
Christian Capitini, MD
University of Wisconsin, Madison – United States
Associate Editors
Ana Carrizosa Anderson, MD
Harvard University – United States
Wolf Hervé Fridman, MD, PhD
Cordeliers Research Center, Paris – France
Bryon D. Johnson, PhD
Medical College of Wisconsin – United States
William J. Murphy, PhD
University of California, Davis – United States
Gabriel Rabinovich, PhD
Instituto de Biologia y Medicina Experimental (IByME) – Argentina
William L. Redmond, PhD
Earle A. Chiles Research Institute – United States
Paul M. Sondel, MD, PhD
University of Wisconsin – United States
Guidelines and Consensus Statements Section
Section Editor
Robert L. Ferris, MD, PhD, FACS
University of Pittsburgh Cancer Institute – United States
Associate Editors
Paulo Antonio Ascierto, MD
Istituto Nazional Tumori-Fondazione 'G.Pascale' – Italy
Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center – United States
Michael R. Bishop, MD
University of Chicago – United States
Michael Platten, MD
Ruprecht-Karls University Heidelberg – Germany
Immune Cell Therapies and Immune Cell Engineering Section
Section Editor
Marcela V. Maus, MD, PhD
Massachusetts General Hospital – United States
Associate Editors
Michael R. Bishop, MD
University of Chicago – United States
Yvonne Y. Chen, PhD
UCLA – United States
Marco L. Davila, MD, PhD
H. Lee Moffitt Cancer Center – United States
Gerald Linette, MD, PhD
University of Pennsylvania – United States
Marco Ruella, MD
University of Pennsylvania – United States
Eric L. Smith, MD, PhD
Memorial Sloan Kettering Cancer Center – United States
Cameron J. Turtle, MBBS, PhD, FRACP
Fred Hutchinson Cancer Research Center – United States
Immunotherapy Biomarkers Section
Section Editor
Ignacio Melero, MD, PhD
University of Navarra – Spain
Deputy Editor
Kurt A. Schalper, MD, PhD
Yale School of Medicine – United States
Associate Editors
Luigi Buonaguro, MD
Istituto Nazionale Tumori, IRCCs, Fondazione Pascale Napoli – Italy
Lisa H. Butterfield, PhD
Parker Institute for Cancer Immunotherapy – United States
Alessandra Cesano, MD, PhD
ESSA Pharma Inc. – United States
Priti S. Hegde, PhD
Foundation Medicine – United States
Michael D. Kalos, PhD
Janssen Oncology – United States
Thomas O. Kleen, PhD
Precision for Medicine – Germany
Rejean Lapointe, PhD
Universite De Montreal, University Hospital (CRCHUM) – Canada
Christian H. Ottensmeier, MD, PhD, FRCP
University of Southampton – United Kingdom
Licia Rivoltini, MD
Fondazione IRCCS Istituto Nazionale Tumori – Italy
Kimberly A. Shafer-Weaver, PhD
Merck & Co. – United States
Craig L. Slingluff Jr., MD
University of Virginia – United States
Alexandra Snyder Charen, MD
Merck & Co. – United States
Ena Wang, MD
Allogene Therapeutics – United States
Jinada Yuan, MD, PhD
Merck & Co. – United States
Oncolytic and Local Immunotherapy Section
Section Editor
Howard L. Kaufman, MD, FACS
Replimune Group Inc. – United States
Associate Editors
John C. Bell, PhD
Ottawa Hospital Research Institute – Canada
Kevin Harrington, PhD, FRCP, FRCR
The Institute of Cancer Research – United Kingdom
Samuel Rabkin, PhD
Massachusetts General Hospital – United States
Stephen J. Russell, MD, PhD
Mayo Clinic College of Medicine – United States
Ann W. Silk, MD, MS
Dana-Farber Cancer Institute – United States
Reviews Section
Section Editors
Sandra Demaria, MD
Weill Cornell Medical College – United States
Thomas F. Gajewski, MD, PhD
University of Chicago – United States
Associate Editors
Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Care Center – United States
Ira Mellman, PhD
Genentech – United States
James J. Mule, PhD
Moffitt Cancer Center – United States